Current News

	Search for:		in:

Target:

Full text

Title

Company name

Division:

Country:

From:

To:

Operation:		OR		AND
Search for:		partial		exact

Overview

Companies

Countries

Nobilon acquires rights to EBx cell lines from Vivalis for development, production and marketing of influenza vaccines

01 Jun 2007 - Nobilon and Vivalis announced that Nobilon (part of Organon, the human healthcare business unit of Akzo Nobel) has acquired rights from Vivalis to its EBx® cell lines (derived from avian embryonic stem cells) and related technology platform for the development, production and marketing of human influenza vaccines, including seasonal and pandemic.

The licence is world-wide and non-exclusive. The financial terms of the agreement, which remain confidential, include an upfront payment, milestone payments and royalties.

Additional information

Akzo Nobel nv
Amsterdam, Netherlands

News

	21 Nov 2007 -	Akzo Nobel completes OBS sale
	02 Nov 2007 -	Organon signs an exclusive, worldwide licence agreement on advanced antithrombotic compounds with Endotis Pharma
	28 Sep 2007 -	European expert consortium combines forces to develop a novel pandemic influenza vaccine
more news

Nobilon International BV
Boxmeer, Netherlands

Company

Buyer's Guide entry of Nobilon International BV

News

		28 Sep 2007 -	European expert consortium combines forces to develop a novel pandemic influenza vaccine
		10 Nov 2006 -	Organon BioSciences appoints Joost Helsen as General Manager of Nobilon
		20 Oct 2005 -	Nobilon receives European GMP approval for production of Influenza vaccines for clinical trials

N.V. Organon
Oss, Netherlands

Company

Buyer's Guide entry of N.V. Organon

News

	21 Nov 2007 -	Akzo Nobel completes OBS sale
	02 Nov 2007 -	Organon signs an exclusive, worldwide licence agreement on advanced antithrombotic compounds with Endotis Pharma
	28 Sep 2007 -	European expert consortium combines forces to develop a novel pandemic influenza vaccine
more news